In June 2026, Euroimmun received official confirmation from TÜV Rheinland LGA Products GmbH that all of its in vitro diagnostic devices currently on the market under Directive 98/79/EG (IVDD) may continue to be marketed in the European Union. This confirmation applies to all devices for which Euroimmun had submitted a corresponding application based on EU […]
The integration of Immunodiagnostic Systems (IDS) products into the Euroimmun portfolio has created a unique and broad menu of speciality testing solutions. Our combined chemiluminescence immunoassay (ChLIA) range now spans more than 200 analytes from six diagnostic areas: endocrinology, autoimmunity, infectious diseases, allergy, Alzheimer’s disease and therapeutic drug monitoring. ChLIAs from multiple diagnostic areas can
Vesicular glutamate transporter 2 (VGLUT2) has been identified as a novel target antigen of autoantibodies in patients with neurological disorders, frequently accompanied by comorbidities with cardiovascular and inflammatory involvement. The discovery was made in a collaborative study between Euroimmun and different laboratories and clinics in Germany, which was published recently in the journal Brain, Behavior,
Autoantibodies targeting the protein RGS8 (regulator of G-protein signaling 8) are associated with a particular subtype of Hodgkin’s lymphoma, as described in a recently published study performed in a collaboration between EUROIMMUN and research institutes in France, Spain and USA. The novel autoantibodies are suggested to be of at least intermediate risk for paraneoplastic neurological
A novel cell-based immunofluorescence assay (CBA) provides sensitive and specific detection of IgM antibodies against myelin-associated glycoprotein (MAG), as demonstrated in a study published in collaboration with scientists from the University of Verona and the Pediatric Research Institute in Padua, Italy. The Anti-MAG CBA is now available for research use*. Anti-MAG-IgM antibodies are markers for
